Outcomes of treatment groups during the 12 months study
| Placebo | Ciclosporin | |||
|---|---|---|---|---|
| Baseline | 48 weeks | Baseline | 48 weeks | |
| *p<0.05, **p<0.001—significant differences from baseline; †p<0.05—significant between-group differences. | ||||
| TJI, mean (SD) | 44.3 (38.2) | 27.4 (27)** | 35.4 (34.8) | 23.4 (37)** |
| TJC, mean (SD) | 28.3 (19.2) | 19.7 (17.9)** | 22.6 (15.9) | 15. 3 (16.5)** |
| SJC, mean (SD) | 11.7 (8.6) | 7.9 (5) | 11.7 (9.7) | 6.7 (6.5)** |
| ESR (mm/1st h), mean (SD) | 24.5 (19.3) | 22.9 (14.9) | 24.6 (21.6) | 25.5 (17.3) |
| CRP (mg/l), mean (SD) | 15.4 (13.3) | 12.6 (9) | 17.4 (14.5) | 12.7 (14.3)* |
| PASI, mean (SD) | 2.2 (2.7) | 1.9 (2.8) | 2 (2.3) | 0.8 (1.3)**† |
| Patient global pain (VAS/cm), mean (SD) | 5.1 (2.3) | 4.9 (2.9) | 4.7 (2.2) | 3.9 (2.4) |
| Patient global disease activity (VAS/cm), mean (SD) | 5.4 (2.2) | 4.9 (2.8) | 5.1 (2.3) | 4.1 (2.7) |
| HAQ, mean (SD) | 1.1 (0.45) | 0.9 (0.52) | 1.0 (0.62) | 0.9 (0.61) |